GSK on Track for 22 Phase III Trial Starts in 2026
GSK says 18 of the 22 planned Phase III trial starts for 2026 are to date.
Related stories
Garrett Motion shares rise 5.2% after Q3 earnings
Garrett Motion shares rose 5.2% in Thursday trading after the company reported Q3 earnings and higher net sales.
M impact | EQUITY | Oct 29, 2026, 02:40 PM UTC
Nextensa Sells Luxembourg Office Building for EUR43.5 Million
Nextensa announced the sale of a Luxembourg office building to Centre Hospitalier de Luxembourg for EUR43.5 million.
L impact | EQUITY | Oct 29, 2026, 02:40 PM UTC
Shenzhen Longsys Electronics Reports Quarterly Revenue of RMB 14.63 Billion
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
SUMMI Group Delays FY26 Annual Results Publication
SUMMI Group’s FY26 annual results publication is delayed due to audit procedures.
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
Shenzhen Longsys Electronics Reports Quarterly Net Profit of RMB 3.74 Billion
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
Insperity Shares Fall More Than 13% After Q3 Results and Updated Guidance
Insperity shares fell more than 13% after the company reported third-quarter results and updated its 2026 adjusted earnings guidance.
M impact | EQUITY | Oct 29, 2026, 02:38 PM UTC